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Sarcopenia, defined as the loss of skeletal muscle mass and strength,[1](#jcsm12115-bib-0001){ref-type="ref"} is one of the criteria for cancer cachexia.[2](#jcsm12115-bib-0002){ref-type="ref"} A computed tomography (CT) scan has been accepted as one of the most preferred tools to assess sarcopenia.[2](#jcsm12115-bib-0002){ref-type="ref"} Measuring the extent of sarcopenia by CT in patients with malignancy has several advantages, including accurate quantification of muscle mass, precise differentiation between fat and muscle, and wide availability as a routine diagnostic tool in cancer.[3](#jcsm12115-bib-0003){ref-type="ref"}, [4](#jcsm12115-bib-0004){ref-type="ref"} Sarcopenia evaluated by CT is known to be related to an increased risk of chemotherapy toxicity,[5](#jcsm12115-bib-0005){ref-type="ref"}, [6](#jcsm12115-bib-0006){ref-type="ref"} poorer functional status,[7](#jcsm12115-bib-0007){ref-type="ref"} and reduced survival[8](#jcsm12115-bib-0008){ref-type="ref"}, [9](#jcsm12115-bib-0009){ref-type="ref"}, [10](#jcsm12115-bib-0010){ref-type="ref"} in malignancy.

Non‐Hodgkin\'s lymphoma (NHL) is the ninth most common neoplasm in Korea, and diffuse large B‐cell lymphoma (DLBCL) is the most common NHL in adults.[11](#jcsm12115-bib-0011){ref-type="ref"}, [12](#jcsm12115-bib-0012){ref-type="ref"} The International Prognostic Index (IPI), consisting of age, serum lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) performance status (PS), Ann Arbor stage, and sites of involvement, have been used for risk stratification of patients with DLBCL.[13](#jcsm12115-bib-0013){ref-type="ref"} Because the addition of rituximab (R) to the 'conventional' cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen resulted in a dramatic improvement in survival in all age groups of patients with DLBCL,[14](#jcsm12115-bib-0014){ref-type="ref"}, [15](#jcsm12115-bib-0015){ref-type="ref"}, [16](#jcsm12115-bib-0016){ref-type="ref"}, [17](#jcsm12115-bib-0017){ref-type="ref"} the IPI does not identify a risk group with a less than 50% chance of survival.[18](#jcsm12115-bib-0018){ref-type="ref"}, [19](#jcsm12115-bib-0019){ref-type="ref"} New prognostic scoring systems, such as the revised IPI (R‐IPI)[18](#jcsm12115-bib-0018){ref-type="ref"} and an enhanced IPI using the National Comprehensive Cancer Network database (NCCN‐IPI),[19](#jcsm12115-bib-0019){ref-type="ref"} have been introduced and show a better capacity to predict the prognosis of patients with DLBCL than the conventional IPI. These two prognostic indices do not include any other clinical factor beyond those used in the conventional IPI.

Recently, it was reported that sarcopenia is an independent prognostic factor in patients with DLBCL. Lanic *et al.* first showed that the 2 year overall survival (OS) rate was significantly lower in a sarcopenic group than in a non‐sarcopenic group in a study of 82 elderly patients with DLBCL.[20](#jcsm12115-bib-0020){ref-type="ref"} In that study, a score incorporating sarcopenia and hypoalbuminaemia was more prognostic than either factor alone.[20](#jcsm12115-bib-0020){ref-type="ref"} Additionally, the authors suggested that a composite score, including adipopenia and sarcopenia, the so‐called cachexia score, can also be useful to predict outcomes in elderly patients with DLBCL, independent of body mass index (BMI) and the IPI.[21](#jcsm12115-bib-0021){ref-type="ref"} These two previous studies, however, included small numbers of patients and excluded younger patients. Moreover, the scoring systems suggested in these studies are difficult to apply clinically, because well‐known prognostic factors were not included at all in these scoring systems.

In this study, we investigated the prognostic value of sarcopenia in all age groups of patients with DLBCL using an extended cohort. Additionally, a new prognostic model, including sarcopenia and other significant prognostic factors, was constructed using a nomogram.

Methods {#jcsm12115-sec-0006}
=======

Patients {#jcsm12115-sec-0007}
--------

We retrospectively reviewed all consecutive patients histologically confirmed with DLBCL and treated with induction R‐CHOP immunochemotherapy between June 2003 and February 2015 at Gyeongsang National University Hospital (GNUH). Of these patients, those for whom a pre‐treatment CT scan of the chest was available were screened in the study. The following patients were excluded: (i) aged younger than 18 years, (ii) received induction therapy other than standard R‐CHOP‐21 immunochemotherapy, (iii) Richter\'s transformation from chronic lymphocytic leukaemia, and (iv) cases with missing values in any one of the baseline characteristics. This study was approved by the Institutional Review Board of GNUH.

Muscle mass measurement {#jcsm12115-sec-0008}
-----------------------

CT examinations were performed using a 64‐detector CT (Brilliance‐64; Philips Medical Systems, The Netherlands). CT was performed with a detector configuration of 64 × 0.625 mm, a tube voltage of 120 kVp, a fixed tube current of 200 mAs, a pitch of 0.923, a gantry rotation time of 0.5 s, and a smooth reconstruction (Philips 'B') filter. The patient, in the arm‐raised position, was asked to hold his breath at full inspiration. The whole lung parenchyma, from the lung apex to the diaphragm, was scanned in the craniocaudal direction. Iohexol (80 mL; Omnipaque 350, GE Healthcare, Waukesha, WI, USA) was delivered at a rate of 2.5 mL/s. Bolus tracking was performed in the aortic arch with an attenuation threshold of 150 Hounsfield unit (HU). A minimal scan delay of 7 s was applied for each scan.

The mass of the pectoralis muscle, including the pectoralis major and the pectoralis minor, was measured by one radiologist with 7 years of experience. The measurement method was as follows. Reconstructed axial images with a 3 mm slice thickness and 3 mm interval were analysed at the level of the fourth thoracic vertebra using CT histogram software (the 'X section' analysis tool, Advantage Window 4.4; GE Healthcare). Second, the region of interest was placed as the outermost border of muscles using freehand manual drawing. Third, the area of these muscles, which ranged from −29 to 100 HU, was calculated using CT histogram analysis. Then, the mass of the muscles was calculated as the cross‐sectional area. Fourth, the bilateral masses of the muscles were measured separately, and both values were averaged. The muscle mass area was divided by height, and this value was reported as the T4 skeletal muscle index (T4 SMI, cm^2^/m^2^).

Clinical data collection and definitions {#jcsm12115-sec-0009}
----------------------------------------

Clinical data were collected by reviewing electronic medical records. Patients in the sex‐specific lowest quartile of T4 SMI were considered to be the sarcopenic group, and the rest were the non‐sarcopenic group. The IPI, R‐IPI, and NCCN‐IPI were calculated in all patients and compared between the sarcopenic and non‐sarcopenic groups. Elevated LDH was defined as serum LDH \> 225 IU/L and hypoalbuminaemia as serum albumin \< 3.5 g/dL. Treatment response was assessed in available cases according to the revised International Working Group response criteria.[22](#jcsm12115-bib-0022){ref-type="ref"} Treatment toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria (ver. 4.0). Treatment‐related mortality (TRM) was defined as death from any cause other than disease progression within 30 days of the last cycle of R‐CHOP immunochemotherapy or death caused directly by treatment at any time. Treatment completion was defined when a minimum of six cycles of R‐CHOP for localized or advanced disease and three to four cycles of R‐CHOP plus involved field radiotherapy for localized disease were performed. BMI was calculated from measured weight and height at pre‐treatment as kg/m^2^. Underweight was defined as BMI \< 18.5 kg/m^2.^ [23](#jcsm12115-bib-0023){ref-type="ref"}

Statistical analysis {#jcsm12115-sec-0010}
--------------------

A value of *P* \< 0.05 was considered to indicate statistical significance. Comparisons between the two groups were performed using the χ^2^ or Fisher\'s exact test for categorical variables and the Mann--Whitney *U*‐test for continuous data. Correlations among continuous variables were tested using the Pearson correlation coefficient. Progression‐free survival (PFS) was defined as the time from the start of treatment to first progression, death from any cause, or last follow‐up. OS was defined as the time from the start of treatment to death from any cause or last follow‐up. Kaplan--Meier curves for PFS and OS were plotted and compared using the log‐rank test. Cox regression analysis was performed to identify independent prognostic factors. The proportional hazard assumption was satisfied for all variables tested by examining plots of the log minus log survival function. Potentially significant variables (*P* \< 0.10) in univariate analyses were included in a multivariate analysis, and a backward elimination method with the Akaike information criterion (AIC) as a stopping rule[24](#jcsm12115-bib-0024){ref-type="ref"} was used to construct the final model. Then, a nomogram to predict the 3 and 5 year OS rates was developed from the final model to visualize the prognostic value of each risk factor. The predictive accuracy of the nomogram was evaluated by discrimination and calibration. Discrimination was measured via the concordance index (*c* index) with its respective confidence interval (CI), which quantifies the level of concordance between predicted probabilities and the actual chance of having the event of interest.[25](#jcsm12115-bib-0025){ref-type="ref"} A *c* index of 0.5 indicates that outcomes are completely random, whereas a *c* index of 1 indicates that the model is a perfect predictor. To reduce overfit bias, the bias‐corrected *c* index of the nomogram was calculated using 200 bootstrap samples. The nomogram and other prognostic indices were compared with the −2 log likelihood (−2LL) and the AIC in terms of goodness of fit, as well as by using the *c* index. Calibration was assessed by reviewing the plot of predicted probabilities from the nomogram vs. the actual probabilities, again using 200 bootstrap samples.[25](#jcsm12115-bib-0025){ref-type="ref"} The nomogram and its calibration plot were produced using the 'R' software (ver. 3.1.3; R Foundation for Statistical Computing, Vienna, Austria). All other statistical analyses were performed using the SPSS software (ver. 21.0; SPSS Inc., Chicago, IL, USA).

Results {#jcsm12115-sec-0011}
=======

Patient characteristics {#jcsm12115-sec-0012}
-----------------------

In total, 187 patients were included according to the eligibility criteria. In this cohort, T4 SMI was weakly but significantly associated with BMI (*r* = 0.203, *P* = 0.005; *Figure* S1). The first quartile values of T4 SMI were 440 cm^2^/m^2^ (range: 219--967 cm^2^/m^2^) in male patients and 310 cm^2^/m^2^ (range: 189--630 cm^2^/m^2^) in female patients. In total, 46 patients with a value of T4 SMI less than the first quartile were classified as the sarcopenic group, with the remaining 141 patients classified as the non‐sarcopenic group. A comparison of patient characteristics between the two groups is shown in Table [1](#jcsm12115-tbl-0001){ref-type="table-wrap"}. The median age was higher in the sarcopenic group (66.5 years) than in the non‐sarcopenic group (60 years; *P* = 0.014). The proportions of patients with B symptoms (34.8 vs. 17.0%, *P* = 0.011) and hypoalbuminaemia (58.7 vs. 24.1%, *P* \< 0.001) were also higher in the sarcopenic group than in the non‐sarcopenic group. In addition, the sarcopenic group had significantly more advanced IPI (*P* = 0.012), R‐IPI (*P* = 0.015), and NCCN‐IPI (*P* = 0.038) than did the non‐sarcopenic group.

###### 

Patients\' characteristics

  Factor                                                  Sarcopenic (*n* = 46)   Non‐sarcopenic (*n* = 141)   *P*
  ------------------------------------------------------- ----------------------- ---------------------------- ---------
  Age, years                                              0.014                                                
  Median                                                  66.5                    60                           
  Range                                                   24--89                  17--86                       
  Sex                                                                                                          0.876
  Male                                                    28 (60.9)               84 (59.6)                    
  Female                                                  18 (39.1)               57 (40.4)                    
  ECOG PS                                                                                                      0.071
  0--1                                                    29 (63.0)               108 (76.6)                   
  2--3                                                    17 (37.0)               33 (23.4)                    
  B‐symptoms                                                                                                   0.011
  Absent                                                  30 (65.2)               117 (83.0)                   
  Present                                                 16 (34.8)               24 (17.0)                    
  Bulky disease                                                                                                0.158
  Non‐bulky                                               35 (76.1)               120 (85.1)                   
  Bulky                                                   11 (23.9)               21 (14.9)                    
  Ann Arbor stage                                                                                              0.183
  I--II                                                   17 (37.0)               68 (48.2)                    
  III--IV                                                 29 (63.0)               73 (51.8)                    
  Extranodal involvement                                                                                       0.142
  0--1 site                                               28 (60.9)               102 (72.3)                   
  \>1 site                                                18 (39.1)               39 (27.7)                    
  LDH                                                                                                          0.683
  Normal                                                  18 (39.1)               60 (42.6)                    
  Elevated                                                28 (60.9)               81 (57.4)                    
  IPI                                                                                                          0.012
  Low to low intermediate                                 19 (41.3)               88 (62.4)                    
  High intermediate to high                               27 (58.7)               53 (37.6)                    
  R‐IPI                                                                                                        0.015
  Very good                                               3 (6.5)                 26 (18.4)                    
  Good                                                    17 (37.0)               67 (47.5)                    
  Poor                                                    26 (56.5)               48 (34.0)                    
  NCCN‐IPI                                                                                                     0.038
  Low to low intermediate                                 17 (37.0)               77 (54.6)                    
  High intermediate to high                               29 (63.0)               64 (45.4)                    
  Albumin                                                                                                      \<0.001
  Normal                                                  19 (41.3)               107 (75.9)                   
  Hypoalbuminaemia                                        27 (58.7)               34 (24.1)                    
  Treatment response                                                                                           0.004
  CR                                                      27 (58.7)               114 (80.9)                   
  PR, SD, or PD                                           11 (23.9)               20 (14.2)                    
  Not available[a](#jcsm12115-note-0004){ref-type="fn"}   8 (17.4)                7 (5.0)                      

Data are presented as number of patients (%) except age.

ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; R‐IPI, revised International Prognostic Index; NCCN‐IPI, National Comprehensive Cancer Network International Prognostic Index; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

Information for treatment response was not available in 15 patients because of the following reasons: early discontinuation of treatment because of treatment toxicity after the first cycle of chemotherapy (eight patients), patient\'s own will to withdraw the treatment (five patients), and loss of follow‐up (two patients).

Treatment toxicity, compliance, and response {#jcsm12115-sec-0013}
--------------------------------------------

Toxicity and compliance of R‐CHOP immunochemotherapy were compared between the sarcopenic and non‐sarcopenic groups (Table [2](#jcsm12115-tbl-0002){ref-type="table-wrap"}). The rate of grade 3--4 anaemia in the sarcopenic group was higher than in the non‐sarcopenic group (34.8 vs. 12.1%, *P* \< 0.001). Grade 3--4 thrombocytopenia was more likely to occur in the sarcopenic group than in the non‐sarcopenic group (30.4 vs.17.7%, *P* = 0.066). Although there was no difference in grade 3--4 neutropenia, the rate of grade 3 or greater febrile neutropenia was significantly higher in the sarcopenic group than in the non‐sarcopenic group (47.8 vs. 28.4%, *P* = 0.015). Grade 4--5 non‐haematologic toxicity was also more commonly observed in the sarcopenic group than the non‐sarcopenic group (19.6 vs. 6.4%, *P* = 0.017). In the sarcopenic group, 21.7% (vs. 5.0% in the non‐sarcopenic group, *P* = 0.002) and 32.6% (vs. 14.9% in the non‐sarcopenic group, *P* = 0.008) of patients experienced TRM and did not complete the treatment, respectively.

###### 

Comparison of toxicity and compliance for immunochemotherapy according to sarcopenia status

                                                                               Sarcopenic (*n* = 46)   Non‐sarcopenic (*n* = 141)   *P*
  ---------------------------------------------------------------------------- ----------------------- ---------------------------- ---------
  Grade 3--5 haematologic toxicity                                                                                                  
  Anaemia[a](#jcsm12115-note-0006){ref-type="fn"}                              16 (34.8)               17 (12.1)                    \<0.001
  Neutropenia[a](#jcsm12115-note-0006){ref-type="fn"}                          35 (76.1)               120 (85.1)                   0.158
  Thrombocytopenia[a](#jcsm12115-note-0006){ref-type="fn"}                     14 (30.4)               25 (17.7)                    0.066
  Febrile neutropenia                                                          22 (47.8)               40 (28.4)                    0.015
  Any grade 3--5 non‐haematologic toxicity                                     20 (43.5)               46 (32.6)                    0.181
  Any grade 4--5 non‐haematologic toxicity                                     9 (19.6)                9 (6.4)                      0.017
  Treatment‐related mortality                                                  10 (21.7)               7 (5.0)                      0.002
  Treatment completion                                                                                                              0.008
  Completed                                                                    31 (67.4)               120 (85.1)                   
  Discontinued because of any reason[b](#jcsm12115-note-0007){ref-type="fn"}   15 (32.6)               21 (14.9)                    

Data are presented as number of patients having an event (%).

Grade 3--4.

One sarcopenic and two non‐sarcopenic patients discontinued the treatment after three cycles of R‐CHOP because of early disease progression but not because of treatment toxicity.

Treatment response could be assessed in 172 of 187 patients (Table [1](#jcsm12115-tbl-0001){ref-type="table-wrap"}). Information for treatment response was not available in 15 patients for the following reasons: early discontinuation of treatment because of treatment toxicity after the first cycle of R‐CHOP (eight patients), patient\'s own wish to withdraw the treatment (five patients), and loss to follow‐up (two patients). Among the total of 187 patients, the rate of complete response (CR) was much lower in the sarcopenic group than in the non‐sarcopenic group (58.7 vs. 80.9%, *P* = 0.004). When treatment response was evaluated in 154 patients, excluding those who discontinued treatment because of any cause other than early disease progression, however, there was no statistically significant difference in the CR rate between the sarcopenic and non‐sarcopenic groups (78.1 vs. 90.2%, *P* = 0.076).

Survival analysis {#jcsm12115-sec-0014}
-----------------

Overall, with a median follow‐up duration of 60.9 months (range: 0.2--145.3 months), the 5 year PFS and OS rates were 58.4 and 60.7%, respectively. The 5 year PFS rate (35.3 vs. 65.8%, *P* \< 0.001; *Figure* [1](#jcsm12115-fig-0001){ref-type="fig"}A) and the 5 year OS rate (37.3 vs. 68.1%, *P* \< 0.001; *Figure* [1](#jcsm12115-fig-0001){ref-type="fig"}B) were significantly lower in the sarcopenic group than in the non‐sarcopenic group. Subgroup analysis revealed a survival disadvantage in the sarcopenic group in nearly all subgroups (*Figure* [2](#jcsm12115-fig-0002){ref-type="fig"}).

![Kaplan--Meier plots for (A) progression‐free survival and (B) overall survival according to sarcopenia status.](JCSM-7-567-g001){#jcsm12115-fig-0001}

![Forest plot for the subgroup analysis of overall survival.](JCSM-7-567-g002){#jcsm12115-fig-0002}

On univariate analyses, the five components of the IPI, B symptoms, hypoalbuminaemia, and sarcopenia were associated with worse PFS and OS. On multivariate analysis, sarcopenia was one of the independent poor prognostic factors for PFS \[hazard ratio (HR) = 2.074, 95% CI: 1.298‐3.312, *P* = 0.002\] and OS (HR = 2.112, 95% CI: 1.299‐3.435, *P* = 0.003), together with the five components of the IPI (Table [3](#jcsm12115-tbl-0003){ref-type="table-wrap"}).

###### 

Univariate and multivariate analyses for PFS and OS

  Factor                   PFS     OS                                                                                                              
  ------------------------ ------- -------------- --------- ------- -------------- ------- ------- -------------- --------- ------- -------------- ---------
  Age, years                                                                                                                                       
  ≤60                      Ref.                             Ref.                           Ref.                             Ref.                   
  \>60                     2.969   1.801--4.894   \<0.001   1.947   1.152--3.288   0.013   3.580   2.077--6.171   \<0.001   2.522   1.435--4.434   0.001
  Sex                                                                                                                                              
  Female                   Ref.    Ref.                                                                                                            
  Male                     1.362   0.860--2.158   0.187     ---                            1.304   0.808--2.107   0.277     ---                    
  ECOG PS                                                                                                                                          
  0--1                     Ref.                             Ref.                           Ref.                             Ref.                   
  2--3                     3.451   2.187--5.447   \<0.001   2.323   1.419--3.805   0.001   4.049   2.513--6.524   \<0.001   2.592   1.551--4.333   \<0.001
  B‐symptoms                                                                                                                                       
  Absent                   Ref.    Ref.                                                                                                            
  Present                  3.037   1.911--4.826   \<0.001   ---                            3.171   1.964--5.119   \<0.001   ---                    
  Bulky disease                                                                                                                                    
  Non‐bulky                Ref.    Ref.                                                                                                            
  Bulky                    0.718   0.378--1.362   0.310     ---                            0.788   0.413--1.504   0.470     ---                    
  Ann Arbor stage                                                                                                                                  
  I--II                    Ref.    Ref.           Ref.      Ref.                                                                                   
  III--IV                  4.569   2.689--7.764   \<0.001   2.619   1.332--5.150   0.005   4.350   2.513--7.532   \<0.001   2.457   1.194--5.057   0.015
  Extranodal involvement                                                                                                                           
  0--1 site                Ref.    Ref.                     Ref.    Ref.                                                                           
  \>1 site                 4.637   2.937--7.322   \<0.001   1.906   1.078--3.371   0.027   4.625   2.864--7.466   \<0.001   1.990   1.076--3.683   0.028
  s                                                                                                                                                
  Normal                   Ref.    Ref.           Ref.      Ref.                                                                                   
  Elevated                 2.930   1.770--4.851   \<0.001   1.903   1.106--3.274   0.020   3.346   1.954--5.731   \<0.001   2.250   1.256--4.032   0.006
  Albumin                                                                                                                                          
  Normal                   Ref.    Ref.                                                                                                            
  Hypoalbuminaemia         3.188   2.050--4.959   \<0.001   ---                            3.738   2.349--5.950   \<0.001   ---                    
  BMI                                                                                                                                              
  Normal to obese          Ref.    Ref.                                                                                                            
  Underweight              1.657   0.720--3.813   0.235     ---                            1.815   0.786--4.190   0.163     ---                    
  Sarcopenia                                                                                                                                       
  Non‐sarcopenic           Ref.    Ref.           Ref.      Ref.                                                                                   
  Sarcopenic               2.583   1.643--4.059   \<0.001   2.074   1.298--3.312   0.002   2.681   1.674--4.294   \<0.001   2.112   1.299--3.435   0.003

PFS, progression‐free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; BMI, body mass index.

Prognostic nomogram for OS {#jcsm12115-sec-0015}
--------------------------

A nomogram for predicting OS was constructed using the six significant prognostic factors (sarcopenia and the five components of the IPI) determined by the Cox regression analysis (*Figure* [3](#jcsm12115-fig-0003){ref-type="fig"}). ECOG PS was the largest contributor in the nomogram, followed by age, Ann Arbor stage, serum LDH level, sarcopenia, and extranodal involvement. The calibration plot for the probability of 3 and 5 year OS showed a good linear relationship between prediction by the nomogram and actual observations (*Figure* S2). The original *c* index of the nomogram was 0.80 (95% CI: 0.75‐0.85), and the bias‐corrected *c* index was 0.78. The performance of the nomogram was compared with those of other prognostic indices (Table S1). The *c* index of the nomogram (0.80, 95% CI: 0.75‐0.85) was higher than those of the IPI (0.77, 95% CI: 0.72--0.83, *P* = 0.009), the R‐IPI (0.74, 95% CI: 0.68‐0.79, *P* \< 0.001), and the NCCN‐IPI (0.77, 95% CI: 0.72‐0.82, *P* = 0.062). Furthermore, the −2LL and the AIC were lower in the nomogram (599.77 and 611.77), compared with the IPI (613.41 and 615.41), R‐IPI (630.47 and 632.47), and NCCN‐IPI (614.18 and 616.18), indicating that the nomogram was the best fitting model with this cohort.

![Nomogram for predicting 3 and 5 year overall survival rates.](JCSM-7-567-g003){#jcsm12115-fig-0003}

Additionally, the cohort was grouped according to the predicted probability of 5 year OS derived from the nomogram \[predicted 5 year OS rate (nomogram score): ≥90% (0--83), 89--70% (84--211), 69--40% (212--310), and \<40% (\>310)\]. The OS curves were clearly separated according to the nomogram score (*P* \< 0.001; *Figure* [4](#jcsm12115-fig-0004){ref-type="fig"}).

![Kaplan--Meier plots for overall survival according to the nomogram score.](JCSM-7-567-g004){#jcsm12115-fig-0004}

Discussion {#jcsm12115-sec-0016}
==========

First, we investigated whether sarcopenia affected the clinical outcome of patients with DLBCL treated with induction R‐CHOP immunochemotherapy. Sarcopenia was strongly and independently associated with worse PFS and OS in this cohort. The sarcopenic group had more frequent episodes of grade 3 or worse anaemia, thrombocytopenia, and febrile neutropenia than the non‐sarcopenic group. Non‐haematological toxicity of grade 4 or more was also more frequently reported in the sarcopenic group. Consequently, the incidences of TRM and early discontinuation of treatment in the sarcopenic group were much higher than those in the non‐sarcopenic group. Although the CR rate in the sarcopenic group was lower than that in the non‐sarcopenic group in the whole cohort, there was no difference in CR rate between the two groups in whom treatment was not interrupted because of causes other than disease progression. This finding means that a lower treatment response rate in the sarcopenic group resulted from suboptimal treatment because of excessive toxicity rather than tumour responsiveness to the treatment. Thus, it is suggested that the main reason why PFS and OS were worse in the sarcopenic group is intolerance to treatment, related to a lower treatment response rate and to TRM.

There have been many reports on the association between sarcopenia and increased treatment toxicity in solid tumours in the contexts of neoadjuvant chemotherapy,[26](#jcsm12115-bib-0026){ref-type="ref"} adjuvant chemotherapy,[27](#jcsm12115-bib-0027){ref-type="ref"} palliative chemotherapy,[5](#jcsm12115-bib-0005){ref-type="ref"} and treatment with targeted agents.[6](#jcsm12115-bib-0006){ref-type="ref"} The precise mechanism that explains these findings remains unknown. However, several studies suggested that patients with cancer with sarcopenia had relatively increased exposure to drug and thus experienced greater treatment toxicity. In a study of patients with breast cancer receiving adjuvant chemotherapy including epirubicin, lower lean body mass (LBM) was significantly associated with decreased clearance of epirubicin and the presence of dose‐limiting toxicity (DLT).[28](#jcsm12115-bib-0028){ref-type="ref"} Another previous study of patients with hepatocellular carcinoma reported that the sarcopenic group had a higher median area under the curve of sorafenib and experienced more DLTs than did the non‐sarcopenic group.[29](#jcsm12115-bib-0029){ref-type="ref"} A recent study of patients with non‐small cell lung cancer also demonstrated that gemcitabine and vinorelbine doses according to body surface area resulted in a substantial variation of drug dose per kilogram LBM, and higher dose per kilogram LBM was associated with more grade 3--4 haematological toxicity.[30](#jcsm12115-bib-0030){ref-type="ref"} However, increased exposure to drug may have beneficial effects in terms of the tumour response to anticancer therapy. In a study of patients with breast cancer receiving neoadjuvant chemotherapy, the pathological CR rate was higher in sarcopenic patients than in non‐sarcopenic patients among those with a normal BMI.[31](#jcsm12115-bib-0031){ref-type="ref"} The authors mentioned that the sarcopenic patients in their study were relatively healthier and were better able to tolerate chemotherapy than those with advanced cancer assessed in other studies.[31](#jcsm12115-bib-0031){ref-type="ref"} All of these previous studies support our findings that sarcopenia is strongly associated with increased treatment toxicity and early discontinuation of treatment, and poor responses to treatment observed in the sarcopenic group are derived from suboptimal treatment because of toxicity but not from tumour responsiveness itself.

Given the low CR rate and greater treatment toxicity, worse survival in the sarcopenic group was the expected result, consistent with the results of many other studies of solid tumours.[8](#jcsm12115-bib-0008){ref-type="ref"}, [9](#jcsm12115-bib-0009){ref-type="ref"}, [32](#jcsm12115-bib-0032){ref-type="ref"}, [33](#jcsm12115-bib-0033){ref-type="ref"} Nevertheless, because sarcopenia was significantly associated with old age, advanced prognostic indices, and hypoalbuminaemia in this study, whether sarcopenia is truly an independent prognostic factor needs to be clarified. When considering age and prognostic indices, the prognostic value of sarcopenia is independent of these factors, because the sarcopenic group had a worse prognosis than did the non‐sarcopenic group regardless of age and prognostic indices in subgroup analysis, and sarcopenia was one of the independent prognostic factors in a multivariate analysis adjusting for these factors. In the case of hypoalbuminaemia, there was a strong correlation between sarcopenia and hypoalbuminaemia, and OS was not significantly different between the sarcopenic and non‐sarcopenic groups in the subgroup of patients with hypoalbuminaemia. However, the number of patients with hypoalbuminaemia was rather small to confirm its significance. Furthermore, the prognostic value of sarcopenia was also independent of the presence of hypoalbuminaemia in a multivariate analysis. Lanic *et al.* also showed that the predictive value for PFS and OS of sarcopenia was independent of albumin status in patients with DLBCL.[20](#jcsm12115-bib-0020){ref-type="ref"} These findings demonstrate that sarcopenia can be an additive prognostic factor to the conventional prognostic system of DLBCL.

To confirm the additive prognostic value of and to expand the clinical utility of sarcopenia in DLBCL, we constructed a nomogram predicting the 3 and 5 year OS, based on the final model of the Cox regression analysis including sarcopenia and the components of the IPI. A *c* index of 0.80 in the nomogram indicated excellent discrimination. With the nomogram score, the cohort could be clearly separated into four groups with different prognoses. Moreover, the nomogram was more accurate and appropriate than well‐known prognostic indices, such as the IPI, R‐IPI, and NCCN‐IPI, for predicting prognosis, at least in this cohort. Because the nomogram improved conventional prognostic indices by adding the patient\'s ability to tolerate treatment to well‐known prognostic factors, the nomogram may help to select 'fit' patients for induction R‐CHOP immunochemotherapy and to stratify patients in clinical trials with intensive therapy in DLBCL.

This study had several limitations. First, it used a retrospective design with a small sample size, and thus, it is hard to generalize our findings. To overcome this, we internally validated the model with bootstrap resampling. Furthermore, the sample size of 187 in this study is larger than that of previous studies for sarcopenia in patients with malignant lymphoma.[20](#jcsm12115-bib-0020){ref-type="ref"}, [21](#jcsm12115-bib-0021){ref-type="ref"}, [34](#jcsm12115-bib-0034){ref-type="ref"} Second, this study did not include information about the immunophenotype of DLBCL, such as the germinal center B‐cell (GCB) or the activated B‐cell subtypes. Thus, the relationship between sarcopenia and tumour aggressiveness could not be examined in this study. In a previous study, there was no correlation between sarcopenia and the GCB/non‐GCB subtype in DLBCL.[20](#jcsm12115-bib-0020){ref-type="ref"} Third, compared with the lumbar L3 skeletal muscle, the pectoralis muscle (T4 SMI) used in this study has not yet been validated to define sarcopenia through prospective data. However, measuring the pectoralis muscle area has the advantage that it is easy to identify the muscle area, and it has been demonstrated that the pectoralis muscle area is associated with fat‐free mass.[35](#jcsm12115-bib-0035){ref-type="ref"} Moreover, there was a significant positive correlation between BMI and T4 SMI in this study. Given the paucity of data on these issues, further studies are needed to examine the association between sarcopenia and immunophenotype of DLBCL and to validate the role of the pectoralis muscle area as a surrogate marker for sarcopenia.

In conclusion, this study demonstrates the role of sarcopenia as a poor prognostic marker in patients with DLBCL. We suggest that dose adjustment and intensive supportive care should be considered in patients with DLBCL with sarcopenia receiving induction R‐CHOP immunochemotherapy. Further prospective studies are warranted to confirm the prognostic role of sarcopenia and to externally validate the nomogram including sarcopenia in DLBCL.
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